Graham Capital Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Graham Capital Management, L.P.
- $3.11 Billion
- Q2 2024
A detailed history of Graham Capital Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 66,165 shares of ARQT stock, worth $717,228. This represents 0.02% of its overall portfolio holdings.
Number of Shares
66,165
Previous 13,466
391.35%
Holding current value
$717,228
Previous $133,000
362.41%
% of portfolio
0.02%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
128MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.7MShares$126 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$108 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$106 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$95.2 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$93.5 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $652M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...